Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) price on Thursday, July 24, fall -1.51% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $16.33.
A look at the stock’s price movement, the close in the last trading session was $16.58. Turning to its 52-week performance, $22.80 and $12.47 were the 52-week high and 52-week low respectively. Overall, TEVA moved -4.45% over the past month.
Teva- Pharmaceutical Industries Ltd. ADR’s market cap currently stands at around $18.73 billion, with investors looking forward to this quarter’s earnings report slated for in August.
Analysts have a consensus estimate of 4.28B for the company’s revenue for the quarter, with a low and high estimate of 4.2B and 4.32B respectively. The average forecast suggests up to a 2.67% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 16.97B, representing a 2.57% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that TEVA is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 6 recommend TEVA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
TEVA’s current price about -1.11% and -3.60% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 45.76, while 7-day volatility ratio is 2.02% and 2.26% in the 30-day chart. Further, Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has a beta value of 0.63. Analysts have given the company’s stock an average 52-week price target of $22, forecast between a low of $10 and high of $28. Looking at the price targets, the low is 38.76% off current price level while to achieve the yearly target high, price needs to move -71.46%. Nonetheless, investors will most likely welcome a -34.72% jump to $22 which is the analysts’ median price.
If we refocus on Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA), historical trading data shows that trading volumes averaged 11.60 million over the past 3 months. The company’s latest data on shares outstanding shows there are 1.15 billion shares.
The 0.01% of Teva- Pharmaceutical Industries Ltd. ADR’s shares are in the hands of company insiders while institutional holders own 62.98% of the company’s shares. Current price change has pushed the stock -3.83% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the TEVA stock continues to rise going into the next quarter.
